PLYX (Polaryx Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLYX Polaryx Therapeutics Inc PLYX
13 GF Score
Price $2.26
View Full Analysis

What is Polaryx Therapeutics OCF Margin %?

Polaryx Therapeutics PLYX +2.73% 13 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates PLYX with a GF Score™ of 13/100. Among 950 Biotechnology companies, Polaryx Therapeutics ranks worse than 105263.05% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Polaryx Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-2.06 Mil. Polaryx Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Polaryx Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Polaryx Therapeutics's current OCF Yield % is -4.70%.

The historical rank and industry rank for Polaryx Therapeutics's OCF Margin % or its related term are showing as below:


PLYX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.565
* Ranked among companies with meaningful OCF Margin % only.

Polaryx Therapeutics OCF Margin % Related Terms

Polaryx Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Polaryx Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polaryx Therapeutics OCF Margin % Chart

Polaryx Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
OCF Margin %
0.00 0.00 0.00

Polaryx Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PLYX
13GF Score
Polaryx Therapeutics Inc PLYX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polaryx Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Polaryx Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.944/0
= %

Polaryx Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.063/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Polaryx Therapeutics (PLYX) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Polaryx Therapeutics and its competitors. According to the industry distribution chart, Polaryx Therapeutics ranks #999999 out of 950 companies in the Biotechnology industry.
Is Polaryx Therapeutics' OCF Margin % too high?
Polaryx Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Polaryx Therapeutics ranks #999999 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Polaryx Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Polaryx Therapeutics' OCF Margin % compare to GUTS and NTHI?
According to the Biotechnology industry distribution chart, Polaryx Therapeutics ranks #999999 out of 950 companies for OCF Margin %. This places Polaryx Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Polaryx Therapeutics and its competitors. Polaryx Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaryx Therapeutics stock overvalued right now?
Polaryx Therapeutics (PLYX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Polaryx Therapeutics' overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Polaryx Therapeutics (PLYX), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Polaryx Therapeutics Business Description

Address South Tower, 140 East Ridgewood Avenue, Suite 415, Paramus, NJ, USA, 07652
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
13GF Score

Get the complete analysis for PLYX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.26
Price